Roth Capital Resumes Apexigen Inc (APGN) at Buy, PT $15, 'Activating CD40 to Enhance Immune Response in Cancer'

January 24, 2023 7:45 AM EST Send to a Friend
(Updated - January 24, 2023 7:46 AM EST)

Roth Capital analyst Kumaraguru Raja resumes coverage on Apexigen Inc (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login